Description
Methyldopa Tablet
Methyldopa Tablets IP / BP / USP (250 mg / 500 mg)
Centrally Acting Anti-Hypertensive Maternal Therapeutic
Healthy Life Pharma Private Limited, alongside our specialized global export and marketing division Healthy Inc, is a premier Indian manufacturer, CDMO partner, and wholesale exporter of advanced maternal-fetal health, gynecology, and cardiovascular therapeutics. We manufacture ultra-high-purity, kinetically stable Methyldopa Tablets within our state-of-the-art, WHO–GMP certified solid dosage manufacturing installations.
As a primary, safe therapeutic choice for gestational cardiovascular disorders, this formulation acts as a massive-volume strategic export to maternity hospital cooperatives, state healthcare distribution pipelines, national health ministry procurement tenders, and international digital B2B pharmaceutical marketplaces across Africa, the CIS region, LATAM, and South-East Asia.
Product Overview
This formulation operates as a “Central Sympathetic Outflow Suppressor.” It ensures maternal and fetal safety by modifying neurological vascular signals in the brainstem, safely lowering systemic blood pressure without reducing uterine or placental perfusion.
Mechanism 1 (Active Neurological Conversion): Methyldopa is a structural prodrug that physically crosses the blood-brain barrier via an active amino acid transporter. Once inside central adrenergic neurons, it is chemically metabolized into Alpha-Methylnorepinephrine.
Mechanism 2 (Central Alpha-2 Adrenergic Stimulation): The active metabolite physically acts as a potent agonist, stimulating central Alpha-2 ($α_{2}$) adrenergic receptors located inside the nucleus tractus solitarius of the brainstem.
Mechanism 3 (Sympathetic Outflow Suppression): This central stimulation chemically dampens and suppresses the output of vasoconstrictive sympathetic signals to the peripheral cardiovascular system. The physical result is a steady reduction in peripheral vascular resistance, safely lowering arterial blood pressure while maintaining stable cardiac output and renal blood flow.
Product Composition & Available Strengths
We supply Methyldopa in standard, exact strengths designed to facilitate the careful, progressive dose titration required in gestational healthcare.
| Active Ingredient Monograph | Available Strengths | Formulation Matrix Delivery System | Primary Clinical Application |
| Methyldopa Anhydrous IP / BP / USP | 250 mg | Oral Solid Film-Coated Tablet (Scored for micro-titration) | Initial Titration / Baseline Care: For early-stage gestational hypertension and lower-dose fine-tuning. |
| Methyldopa Anhydrous IP / BP / USP | 500 mg | Oral Solid Film-Coated Tablet (Engineered for uniform mass release) | High-Potency Maintenance: For advanced chronic hypertension during pregnancy and severe pre-eclamptic stabilization. |
Technical & Logistics Specifications
HS Code: 3004.90.69 (Medicaments containing hormones or other products of heading 29.37 but not containing antibiotics / Anti-hypertensives) or 3004.90.99 (General Category)
CAS Number: 41372-08-0 (Methyldopa Sesquihydrate) / 555-30-6 (Methyldopa Anhydrous)
Dosage Form: Oral Solid Film-Coated Tablet (Core matrix film-coated to shield the active chemical from oxidation and mask raw taste profiles)
Packaging Configurations: 10 or 14 Tablets per Blister packed in premium, high-barrier Alu-Alu (Cold-Form Foil) or thick moisture-shield PVC/PVDC strips. Our tropicalized packaging matrices completely block environmental moisture and oxygen, guaranteeing a full 36-month shelf life in hot, humid Zone IVb export environments.
Advanced Manufacturing Integrity & Quality Controls
Oxidation Prevention Processing: Methyldopa raw active substance is highly physically sensitive to ambient oxygen, which chemically causes discoloration and molecular degradation. We maintain our complete blending, granulization, and tableting lines under Strict Climate-Controlled Environments with Nitrogen-Blanketed Blanking Systems, preserving pristine chemical integrity.
High-Speed Content Uniformity Compression: To ensure zero physical weight variations across high-output manufacturing runs, we utilize automated compression suites equipped with Forced Feeder Die Systems and Online Core Hardness Testers, physically guaranteeing that every tablet delivers the exact calibrated therapeutic dose.
Validated Release Kinetics: Every export production batch physically undergoes Automated In-Vitro Dissolution Profiling, chemically verifying that our generic formulations achieve quick disintegration in gastric fluids to maximize rapid, predictable systemic absorption.
Primary Indications
Obstetrics & Gynecology: First-line, safe management of Gestational Hypertension and Pre-Eclampsia in pregnant patients.
Internal Medicine: Treatment of mild, moderate, or severe Chronic Essential Hypertension, specifically when first-line modern blockers cannot be utilized due to patient contraindications.
Usage Instructions
Administration Matrix: Swallow the tablet physically whole with a full glass of water. It can be taken consistently either with or without food.
The Sedation Window: Methyldopa centrally induces mild, transient drowsiness during initialization or when the dose is escalated. To physically minimize this effect, clinical networks recommend administering any newly increased daily doses at bedtime.
Hematological Screening Requirement: Chronic administration can occasionally trigger immune-mediated blood variations. Periodic physical tracking of patient complete blood counts (CBC) and Coombs tests (direct) is highly recommended during prolonged multi-month management.
Safety Warning: CRITICAL FIRST-LINE MATERNAL ANTI-HYPERTENSIVE. For Obstetrician/Physician Supervision Only. Sedation Warning: Centrally induces transient drowsiness, dizziness, or orthostatic hypotension; advise patients to move physically slow during initial titration windows. Hepatic Care Note: Monitor liver parameters chemically ($ALT$/$AST$) during the first 6 to 12 weeks of therapy to check for rare drug-induced hepatic hypersensitivity. Contraindications: Absolute contraindication in patients presenting with active hepatic disease (acute hepatitis, active cirrhosis), monoamine oxidase inhibitor ($MAOI$) co-administration, or a known history of severe hypersensitivity to methyldopa.
Global CDMO Services & Wholesale Supply Chain
Healthy Life Pharma Private Limited and Healthy Inc provide comprehensive, internationally validated Third-Party Contract Manufacturing (CDMO Services) and high-volume private label export supply for the entire Methyldopa dosage spectrum. Whether you are executing a high-volume procurement contract for an African National Maternal and Child Health Tender, supplying a specialized public hospital infrastructure across the CIS region, or injecting premium inventory into an international digital B2B Pharmaceutical Marketplace across Southeast Asia or LATAM, we handle all required technical documentation (WHO-GMP Certificate, Certificates of Pharmaceutical Product – COPP, Certificates of Analysis – COA, Stability Testing Matrix Sheets, and Complete CTD Format Dossier sets) for seamless regulatory clearance.
Commercial & Bulk Procurement Inquiries:
Corporate Head Office: Mumbai, Maharashtra, India
Primary Manufacturing Base: Boisar, Maharashtra, India
WhatsApp / Direct Call: +91 7710003340
Corporate Email: info@healthyinc.co.in
